NISHITA MAYETTE: Open Payments
NPI 1588428973 · MANCHESTER, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,050 in 54 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $1,500 · 2025 $1,050
Food & beverage: $1,040Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $294 |
| Janssen Biotech, Inc. | 7 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $127 |
| Ardelyx, Inc. | 4 | $100 |
| Phathom Pharmaceuticals, Inc. | 8 | $69 |
| Gilead Sciences, Inc. | 3 | $61 |
| Madrigal Pharmaceuticals | 2 | $51 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $45 |
| Exact Sciences Corporation | 1 | $34 |
| Braintree Laboratories, Inc. | 2 | $34 |
Products named: LINZESS, TREMFYA, IBSRELA, VOQUEZNA, ENTYVIO, REZDIFFRA, XIFAXAN, CREON.
Industry payments across CT — which companies pay providers there.
